Showing items 1 - 4 of 4

Your selections:

Lumacaftor/ivacaftor reduces exacerbations in adults homozygous for Phe508del mutation with severe lung disease

- Tong, Koliarne, Barker, Daniel, France, Megan, Burr, Lucy, Greville, Hugh, Visser, Simone, Middleton, Peter, Wainwright, Claire, Dorahy, Douglas, Wark, Peter

Lumacaftor/ Ivacaftor improves ese tolerance in patients with cystic fibrosis and severe airflow obstructionxerci

- Wark, Peter A. B., Cookson, Kim, Thiruchelvam, Theeba, Brannan, John, Dorahy, Douglas J.

An "unlikely" pair: the antimicrobial synergy of polymyxin B in combination with the cystic fibrosis transmembrane conductance regulator drugs KALYDECO and ORKAMBI

- Schneider, Elena K., Azad, Mohammad A. K., Muller, Mark T., Li, Jian, Velkov, Tony, Han, Mei-Ling, Zhou, Qi (Tony), Wang, Jiping, Huang, Johnny X., Cooper, Matthew A., Doi, Yohei, Baker, Mark A., Bergen, Phillip J.

Drug-drug plasma protein binding interactions of ivacaftor

- Schneider, Elena K., Huang, Johnny X., Carbone, Vincenzo, Baker, Mark, Azad, Mohammad A. K., Cooper, Matthew A., Li, Jian, Velkov, Tony

  • 1
  • Disclaimer
  • Privacy
  • Copyright
  • Contact
  • Deposit